Shares of Genfit S.A. (EPA:GNFT – Get Free Report) dropped 1.8% during trading on Tuesday . The stock traded as low as €5.37 ($5.90) and last traded at €5.37 ($5.90). Approximately 284,282 shares traded hands during mid-day trading, The stock had previously closed at €5.47 ($6.01).
Genfit Price Performance
The firm has a 50-day moving average of €4.67 and a 200 day moving average of €4.17.
About Genfit
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Read More
- Five stocks we like better than Genfit
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Best Aerospace Stocks Investing
- Insider Buying Signals Upside for These 3 Stocks
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
